WITHDRAWN: TREATMENT FAILURE AND EMPIRIC ANTIBIOTIC CHOICE FOR HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA: Β-LACTAM/Β-LACTAMASE INHIBITOR COMBINED WITH MACROLID OR FLUOROQUINOLONE ALONE?

Authors

  • Fatma Tokgoz Akyil Department of Chest Diseases, Canakkale Mehmet Akif Ersoy Devlet Hastanesi, Turkey
  • Sumeyye Alparslan Bekir Department of Chest Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Turkey
  • Aylin Gungor Department of Chest Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Turkey
  • Kubra Akyuz Department of Chest Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Turkey
  • Neslihan Kose Department of Chest Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Turkey
  • Hatice Turker Department of Chest Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Turkey
  • Mustafa Akyil Department of Thoracic Surgery, Canakkale Mehmet Akif Ersoy Devlet Hastanesi, Canakkale, Turkey
  • Tülin Sevim Department of Chest Diseases, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Turkey

DOI:

https://doi.org/10.29121/granthaalayah.v7.i7.2019.778

Keywords:

Lactate Dehydrogenase, Lymphocytes, Neutrohils, Pneumonia

Abstract [English]

Background


A considerable percentage of empirical antibiotic treatment fails in hospitalized patients with community-acquired pneumonia (CAP). β-lactams and macrolid (BLM) combination or respiratory fluoroquinolones (FQ) are the most frequently used in these patients. The aim of the present study is to compare the treatment failure (TF) rates in BLM and FQ treatment and to analyze the predictive factors of TF.


Method


Hospitalized patients who were initially treated with either BLM or FQ were included retrospectively and treatment results of the two regimens were compared.


Results


Of the 144 patients included in the study, the mean age was 67±16 and 102 (71%) were male. Each group constituted of 72 patients. Antibiotic selection did not alter TF rates, length of stay (LOS) and 30-day mortality. Baseline higher levels of leucocytes, neutrophils to lymphocytes ratio (NLR), C-reactive protein (CRP), BUN/albumin, lactate dehydrogenase/aspartat aminotransferase (LDH/AST) levels and pneumonia severity index (PSI) scores were detected as predictors of TF.


Conclusion


Empirical treatments with either BLM or FQ do not correlate with TF, LOS and 30-day mortality. NLR, BUN/albumin and LDH/AST may suggest TF. These inexpensive and easily-reachable parameters have the potential as predictors of the treatment outcome in CAP.


 


Notices of retraction


Akyil, F. T., Bekir, S. A., Gungor, A., Akyuz, K., Kose, N., Turker, H., Akyil, M., & Sevim, T. (2019). TREATMENT FAILURE AND EMPIRIC ANTIBIOTIC CHOICE FOR HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA: Β-LACTAM/Β-LACTAMASE INHIBITOR COMBINED WITH MACROLID OR FLUOROQUINOLONE ALONE?. International Journal of Research -GRANTHAALAYAH, 7(7), 360-369. https://doi.org/10.29121/granthaalayah.v7.i7.2019.778



Article retracted by : Editor
Reason(s) for retraction : Author's conflicts of interest

Downloads

Download data is not yet available.

References

Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune I Le, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl. 3):iii1-55. DOI: https://doi.org/10.1136/thx.2009.121434

Pfuntner A, Wier LM, Steiner C; Most Frequent Conditions in U.S. Hospitals, 2010:Statistical Brief #148. 2013 Jan. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK127490/

US Centers for Disease Control and Prevention. FastStats: leading causes of death. http://www.cdc

.gov/nchs/fastats/leading-causes-of-death.htm. Accessed September 4, 2015.

Mandell LA, Wunderink RG, Anzueto A, Barlett JG, Campbell D, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. DOI: https://doi.org/10.1086/511159

Menéndez R, Torres A, Zalacaín R, Martin Villasclaras JJ, Borderias L, Benitez Moya JM, Ruiz-Manzano J, Rodriguez de Castro F, Blanquer J, Perez D, Puzo C, Sanchez Gascon F, Gallardo J, Alvarez C, Molinos L, Nuumofail Group. Risk factors of treatment failure in community acquired pneumonia: Implications for disease outcome. Thorax 2004;59:960-5. DOI: https://doi.org/10.1136/thx.2003.017756

Nie XM, Li YS, Yang ZW, Wang H, Jin SY, Jiao Y, Metersky ML, Huang Y. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clinical Microbiology and Infection, 2018;24(6), 658-e1. DOI: https://doi.org/10.1016/j.cmi.2017.09.014

Kılınç O, Ece T, Arman D. Türk Toraks Derneği pnömoni tanı ve tedavi uzlaşı raporu. Türk Toraks Derg. 2009;10(Suppl. 6):1-24.

Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman Al, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312–23. DOI: https://doi.org/10.1056/NEJMoa1406330

Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal. 2008;179(12):1269-77. DOI: https://doi.org/10.1503/cmaj.080358

Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nüesch E, Pletz MW, Hecht J, Welte T, Bauer TT. Treatment failure in pneumonia: Impact of antibiotic treatment and cost analysis. Eur Respir J 2012;39:611-8. DOI: https://doi.org/10.1183/09031936.00098411

Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. Jama 2016;315(6):593-602. DOI: https://doi.org/10.1001/jama.2016.0115

Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrobial agents and chemotherapy, 2007; 51(11): 3977-82. DOI: https://doi.org/10.1128/AAC.00006-07

Gündüz C, Taşbakan MS, Sayıner A, Çilli A, Kilinç O, Şakar Coşkun A. Factors affecting treatment success in community-acquired pneumonia. Turk J Med Sci 2016; 46:1469-1474. DOI: https://doi.org/10.3906/sag-1502-87

Cataudella E, Giraffa CM, Di Marca S, Pulvirenti A, Alaimo S, Pisano M, Terranova V, Corriere T, Ronsisvalle ML, Di Quattro R, Stancanelli B, Giordano M, Vancheri C, Malatino L. Neutrophil‐to‐lymphocyte ratio: An emerging marker predicting prognosis in elderly adults with community‐acquired pneumonia. J Am Geriatrics Society 2017;65(8):1796-1801. DOI: https://doi.org/10.1111/jgs.14894

Ugajin M, Yamaki K, Yagi T, Asano T. Blood urea nitrogen to serum albumin ratio independently predicts mortality and severity of community-acquired pneumonia. Int J Gen Med. 2012;5:583-89. DOI: https://doi.org/10.2147/IJGM.S33628

Felmingham D, Canton R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007;55:111-8. DOI: https://doi.org/10.1016/j.jinf.2007.04.006

Simonetti AF, van Werkhoven CH, Schweitzer VA, Viasus D, Carratala J, Postma DF, Oosterheert JJ, Bonten MJM. Predictors for individual patient antibiotic treatment effect in hospitalized community-acquired pneumonia patients. Clin Microbiol Infect 2017;23(10):774-e1. DOI: https://doi.org/10.1016/j.cmi.2017.03.010

Doruk S, Tertemiz KC, Kömüs N, Uçan ES, Kilinç O, Sevinç C. Community acquired pneumonia and direct hospital cost. Tuberk Toraks 2009;57(1):48-55.

Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Intern J Antimicr Agents 2015;46(3):242-8. DOI: https://doi.org/10.1016/j.ijantimicag.2015.04.010

Çilli A, Sayıner A, Çelenk B, Şakar Coşkun A, Kılınç O, Hazar A, Aktaş Samur A, Taşbakan S, Waterer GW, Havlucu Y, Kılıç Ö, Tokgöz F, Bilge U. Antibiotic treatment outcomes in community-acquired pneumonia. Turk J Med Sci 2018;48:730-36. DOI: https://doi.org/10.3906/sag-1709-144

Bircan A, Kaya O, Gökirmak M, Ozturk O, Sahin U, Akkaya A. C-reactive protein, leukocyte count and ESR in the assessment of severity of community-acquired pneumonia. Tuberk Toraks, 2006;54(1):22-29.

Coelho L, Póvoa P, Almeida E. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007;11:R92. DOI: https://doi.org/10.1186/cc6105

Angkananard T, Anothaisintawee T, McEvoy M, Attia J, Thakkinstian A. Neutrophil Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis. BioMed Res Int 2018:2703518. DOI: https://doi.org/10.1155/2018/2703518

Tokgoz Akyil F, Yalcinsoy M, Hazar A, Cilli A, Celenk B, Kilic O, Sayıner A, Kokturk N, Sakar Coskun A, Filiz A, Cakır Edis E. Prognosis of hospitalized patients with community-acquired pneumonia. Pulmonology 2018, 24.3: 164-169. DOI: https://doi.org/10.1016/j.rppnen.2017.07.010

Drent M, Cobben NA, Henderson RF, Wouters EF, van-Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996;9(8):1736-42. DOI: https://doi.org/10.1183/09031936.96.09081736

Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H, Wakabayashi T, Nakano T, Ouchi K, Okimoto N. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J. Infect Chemother 2015;21:153–160. DOI: https://doi.org/10.1016/j.jiac.2014.10.008

Nicolini A, Ferraioli G, Ferrari‐Bravo m, Barlascini C, Santo M, Ferrara L. Early non‐invasive ventilation treatment for respiratory failure due to severe community‐acquired pneumonia. Clin Resp J 2016;10(1):98-103. DOI: https://doi.org/10.1111/crj.12184

Downloads

Published

2019-07-31

How to Cite

Akyil, F. T., Bekir, S. A., Gungor, A., Akyuz, K., Kose, N., Turker, H., Akyil, M., & Sevim, T. (2019). WITHDRAWN: TREATMENT FAILURE AND EMPIRIC ANTIBIOTIC CHOICE FOR HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA: Β-LACTAM/Β-LACTAMASE INHIBITOR COMBINED WITH MACROLID OR FLUOROQUINOLONE ALONE?. International Journal of Research -GRANTHAALAYAH, 7(7), 360–369. https://doi.org/10.29121/granthaalayah.v7.i7.2019.778